Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

May 16, 2022

Dr. Clifford Cassidy, an Assistant Professor in the University of Ottawa's Faculty of Medicine’s Department of Cellular & Molecular Medicine (CMM) and a scientist at The Royal's Institute of Mental Health Research (IMHR), is the paper’s first author. Image courtesy of the Faculty of Medicine, University of Ottawa

News | Magnetic Resonance Imaging (MRI)

Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

May 13, 2022

The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media.

News | Contrast Media

Statement from the ACR Committee on Drugs and Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

May 13, 2022

Sponsored Content

Videos | Proton Therapy

HYPERSCAN: Pencil Beam Scanning Delivered at Hyper Speed

Introducing HYPERSCAN , Pencil Beam Scanning Delivery HYPERSCAN enables tumor volumes to be scanned in a matter of ...

October 06, 2014

Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer

New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

April 14, 2022

News | Nuclear Imaging

New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

April 13, 2022

Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.

News | PET-CT

New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

April 11, 2022

News | PET Imaging

CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

April 8, 2022 — The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab ...

April 08, 2022

RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China

News | Treatment Planning

Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

April 07, 2022

Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).

News | Contrast Media

Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

April 06, 2022

GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission Tomography (PET) radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care.

News | PET Imaging

GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

March 29, 2022 — GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission ...

March 29, 2022

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat

News | Prostate Cancer

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

March 28, 2022

With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.

News | Prostate Cancer

SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

March 23, 2022

F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.

News | Coronavirus (COVID-19)

Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

March 23, 2022

CMSU will bring its state-of-the-art AI medical devices to hospitals and local healthcare providers in a unique hands-on experience to create stronger community engagement throughout the year.

News | Digital Radiography (DR)

Canon Medical Systems USA Presents Its First-Ever U.S. Mobile Truck Tour with the Launch of Canon Across America

March 23, 2022 — Canon Medical Systems USA, Inc. (CMSU), a global leader in innovative diagnostic imaging technology, is ...

March 23, 2022